A Randomized, Open-label, 2-Way-Crossover Study Assessing the Bioequivalence Between Single Doses of 500 mg Glucophage Extended Release (GXR) Tablets (Merck/China Nantong-Manufactured) and 500 mg GXR Tablets (Merck/Germany Darmstadt-Manufactured) Under Fed and Fasted State in Two Groups of Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2018
At a glance
- Drugs Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Acronyms Nantong - Darmstadt
- Sponsors Merck KGaA
- 18 Dec 2018 Status changed from recruiting to completed.
- 09 Nov 2018 Planned End Date changed from 28 Apr 2020 to 8 Nov 2018.
- 09 Nov 2018 Planned primary completion date changed from 28 Apr 2020 to 8 Nov 2018.